Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

Meric-Bernstam, Funda; Makker, Vicky; Oaknin, Ana; Oh, Do-Youn; Banerjee, Susana; González-Martín, Antonio; Hae Jung, Kyung; Ługowska, Iwona; Manso, Luis; Manzano, Aránzazu; Melichar, Bohuslav; Siena, Salvatore; Stroyakovskiy, Daniil; Fielding, Anitra; Ma, Yan; Puvvada, Soham; Shire, Norah; Lee, Jung-Yun

doi:10.1200/jco.23.02005

Public

Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

Shared by NobleBlocks on Jan 1, 2024 • 12:00 AM UTC

Authors:

Funda Meric-Bernstam

Vicky Makker

Ana Oaknin

Abstract

PURPOSE Trastuzumab deruxtecan (T-DXd) is a human epidermal growth factor 2 (HER2)–directed antibody-drug conjugate approved in HER2-expressing breast and gastric cancers and HER2-mutant non–small-cell lung cancer. Treatments are limited for other HER2-expressing solid tumors. METHODS This open-labe...

Discussions